Medivir
  • About us
  • Our projects
  • Investors
  • News and media
  • Connect
  • Svenska
About us
  • Medivir in brief
    • Business concept & Strategy
      • Leadership
        • Management team
        • Board of Directors
      • History
        • EFPIA Disclosure
          Our projects
          • Proprietary
            • Fostroxacitabine bralpamide (fostrox)
            • MIV-711
          • Projects for licensing
            • Remetinostat
            • Birinapant
            • USP-7
          • Partnerships
            • Xerclear®
            • MBLI/MET-X
            • MIV-701
          • Publications
            Investors
            • Stock information
              • Reports
                • Financial reports 2025
                • Financial reports 2024
                • Financial reports 2023
                • Financial reports 2022
                • Financial reports 2021
                • Financial reports 2020
                • Financial reports 2019
                • Financial reports 2018
                • Financial reports 2017
                • Financial reports 2016
              • Presentations
                • Presentations 2026
                • Presentations 2025
                • Presentations 2024
                • Presentations 2023
                • Presentations 2022
                • Presentations 2021
              • Press releases
                • Subscribe
              • Calendar
                • DNB Carnegie Healthcare Seminar
                • Interim Report, January - March 2026 (webcast)
                • Annual General Meeting 2026
                • Interim Report, January - June 2026 (webcast)
                • Interim Report, January - September 2026 (webcast)
              • Corporate Governance
                • General Meetings
                  • 2026
                  • 2025
                  • 2024
                  • 2023
                  • 2022
                  • 2021
                  • 2020
                • Rights issue 2025
                  News and media
                    Connect
                    • Connect with Medivir
                      • Partner with Medivir
                        Search
                        Subscribe to press releases
                        Address

                        Medivir AB
                        Box 1086
                        SE-141 22 Huddinge
                        Visit: Lunastigen 5, 2nd floor

                        Phone +46 (0)8 5468 31 00 Email info@medivir.com
                        Our privacy policy

                        Read more

                         

                        Jens Lindberg

                        Chief Executive Officer

                        jens.lindberg@medivir.com
                         

                        Magnus Christensen

                        Chief Financial Officer

                        magnus.christensen@medivir.com